Blue test tubes arranged in a line, disappearing into the background

Drug news

EU approves Trulicity, a GLP-1 agonist for treatment of Type 2 Diabetes-Eli Lilly

Read time: 1 mins

Last updated: 26th Nov 2014

Published: 26th Nov 2014

Source: Pharmawand

Eli Lilly and Company announced that the European Commission granted marketing authorisation for Trulicity (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution designed to improve glycaemic control in adults with Type 2 Diabetes. The medicine comes in a ready-to-use pen with a pre-attached, hidden needle. Trulicity received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on 25 September 2014.

Learning Zone

Weight Management in Type 2 Diabetes

Explore the comorbidity risk of type 2 diabetes (T2D) and obesity, and the current management options available for T2D and weight loss

Learning Zone Homepage

Cardiovascular Metabolism Learning Zone

The cardiovascular metabolism (CVM) Learning Zone hosted on Medthority.com features over 70 expert opinion videos covering type 2 diabetes and hypertension.

How do you prefer to access medical updates and information?

Listen to a podcast

Watch a video

Read an article

Other

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Moderna reports H5 Flu data

Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.

Drug news

Cibotercept in PAH ends

Published: 30th May 2025

Drug news

Khindivi cleared for pediatrics

Published: 30th May 2025

See all news